Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

Here are the 4 abstracts for AACR April 8-10...

2083 Ponatinib potently inhibits the activity of mutant variants of FGFR commonly found in endometrial, lung and other cancers
Monday, Apr 08, 2013, 1:00 PM - 5:00 PM

2084 Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC
Monday, Apr 08, 2013, 1:00 PM - 5:00 PM

3394 Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST
Tuesday, Apr 09, 2013, 8:00 AM -12:00 PM

5655 AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions
Wednesday, Apr 10, 2013, 8:00 AM -12:00 PM



And a special session...

Session Title: Target Validation by Chemical Probes/Designer Chemical Probes and Phenotypic Approach to Drug Discovery
Session Type: Major Symposium
Session Start/End Time: Tuesday, Apr 09, 2013, 8:15 AM -10:15 AM
[Timothy Clackson will describe strategies to target validated kinases with the right small molecules in a talk titled: “Design and development of ponatinib, a pan-BCR-ABL inhibitor for CML”.]


Link for those interested:
http://www.abstractsonline.com/Plan/AdvancedSearch.aspx
(search for Clackson in Author/Presenter Last Name)